Session information

Symposium

[S27] New developments on active targeting DDS research -from basic research to practical application-

Sun. Mar 26, 2023 4:00 PM - 6:00 PM [Room PS1] (1F)

Organizer: Yusuke Kono, Shigetomo Tsujihata

Active targeting drug delivery system (DDS), which is mainly constructed by the conjugation of ligand to drugs or its carriers, has attracted much attention due to worldwide approval of antibody-drug conjugates (ADC). The most famous active targeting DDS is a combination of low molecular weight dugs and antibodies, like ADC. On the other hand, not only antibodies but also sugars, amino acids, and peptide are available as a ligand for active targeting. In addition, as well as low molecular weight dugs, proteins, nucleic acids, and cells are recently used in pharmacotherapeutics. Therefore, a wide variety of active targeting DDS have been developed so far. However, their clinical use is hardly realized.
In this symposium, we have 2 speakers from pharmaceutical companies and 3 speakers from university, and they will introduce us cutting-edge research on practical application and novel concept of active targeting DDS, respectively. Based on these presentations, we would like to discuss the current issues in developing active targeting DDS and future perspectives for its clinical use.

+Add all to schedule

オーガナイザー挨拶・趣旨説明：河野裕允（神戸薬大） (4:00 PM - 4:05 PM)

4:05 PM - 4:27 PM

[S27-01] Active targeting by antibody-drug conjugate “Trastuzumab deruxtecan”

○Yoko Nagai¹ (1. Drug Metab ＆ Pharmacokinet Res Lab, Daiichi Sankyo.)

4:27 PM - 4:49 PM

[S27-02] Development of amino acid modification-based active-targeted drug delivery system

○Hidemasa Katsumi¹, Masaki Morishita¹, Akira Yamamoto¹ (1. Kyoto Pharm Univ.)

4:49 PM - 5:11 PM

[S27-03] Active targeting of therapeutic cells by ligand molecular modification of cell membrane

○Yuriko Higuchi¹ (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)

5:11 PM - 5:33 PM

[S27-04] Development of active-targeting DDS carriers with the high affinity for albumin receptors

○Yu Ishima¹, Toru Maruyama², Masaki Otagiri³, Tatsuhiro Ishida¹ (1. Ins. Biomed. Sci., Tokushima Univ. Grad. Sch., 2. Grad. Sch. Pharm. Sci., Kumamoto Univ., 3. Faculty Pharm. Sci, Sojo Univ.)

5:33 PM - 5:55 PM

[S27-05] Tumor-associated macrophage-targeted drug delivery to overcome tumor immune resistance

○Naozumi Harada¹, Nami Mizoguchi¹, Ayaka Matsumoto¹, Junki Tashiro¹, Yasunari Haseda¹, Tadashi Inoue¹, Takashi Soga¹, Daisuke Muraoka², Akane Yamamichi³, Hideho Okada³, Shin-ichi Sawada⁴, Kazunari Akiyoshi⁴ (1. United Immunity., 2. Aichi Cancer Center., 3. University of California, San Francisco., 4. Grad. Sch. Eng., Kyoto Univ.)